Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia

Br J Haematol. 2020 May;189(4):e150-e154. doi: 10.1111/bjh.16571. Epub 2020 Mar 18.
No abstract available

Keywords: acute lymphoblastic leukaemia; immunoglobulin heavy-chain (IGH); minimal residual disease; next generation sequencing; spike-in control.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • High-Throughput Nucleotide Sequencing / methods*
  • Humans
  • Immunoglobulin Heavy Chains / metabolism*
  • Male
  • Neoplasm, Residual / genetics*
  • Pilot Projects
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Prognosis

Substances

  • Immunoglobulin Heavy Chains